A possible alpha 2-adrenergic component in the in vivo activity of pirenperone.
The study used the loss of the righting reflex in response to the alpha 2-agonist xylazine in an in vivo rat assay to determine possible effects of the LSD antagonist pirenperone at alpha 2-adrenoceptors. Pirenperone antagonized the response and was more potent (ED50: 0.32 mg/kg) than yohimbine (1.25 mg/kg) and piperoxan (3.30 mg/kg). The data suggest that pirenperone may act at alpha 2-adrenoceptors in vivo.
D000818:Animals; D004146:Dioxanes / Q000494:pharmacology; D005260:Female; D019329:Idazoxan; D010880:Piperidines / Q000494:pharmacology*; D010883:Piperoxan / Q000494:pharmacology; D004856:Postural Balance / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects*; D012018:Reflex / Q000187:drug effects; D012702:Serotonin Antagonists / Q000494:pharmacology; D014149:Tranquilizing Agents / Q000494:pharmacology*; D014991:Xylazine / Q000494:pharmacology; D015016:Yohimbine / Q000494:pharmacology
D004146:Dioxanes; D010880:Piperidines; D011942:Receptors, Adrenergic, alpha; D012702:Serotonin Antagonists; D014149:Tranquilizing Agents; D014991:Xylazine; D015016:Yohimbine; D010883:Piperoxan; D019329:Idazoxan; C034177:pirenperone